Drug intelligence / Profile preview

Rengalin

Development stage
Phase 4
Lead developer
Materia Medica Holding
Modality
Small Molecules, Antibody-Based Therapeutics
Administration
Oral
01

Overview

Rengalin is a release-active combination antitussive drug composed of highly diluted antibodies to bradykinin, histamine, and morphine. It is designed to treat both productive and non-productive cough associated with influenza, acute respiratory infections (including pharyngitis, laryngotracheitis), chronic bronchitis, chronic obstructive pulmonary disease (COPD), and other infectious-inflammatory or allergic diseases of the upper and lower respiratory tract. The mechanism of action involves modulation of endogenous target molecules—bradykinin, histamine (H1, H2, H3 receptors), and endogenous opioids—by modifying their interaction with respective receptors. This results in suppression or regulation of the cough reflex at both central and peripheral levels as well as anti-inflammatory effects such as reduced vascular permeability and bronchial spasm. Rengalin has demonstrated efficacy in reducing cough severity from the first day of administration without significant adverse events[1][2][3][4][5][6].

Brand names
Rengalin
Other names
Rengalin liquid
02

Targets

Bradykinin B2 receptorMOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)HRH3 (Histamine Receptor H3)

Beyond the preview

Go deeper on Rengalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rengalin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call